Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate

scientific article

Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P356DOI10.1002/ANA.24471
P3181OpenCitations bibliographic resource ID2443642
P932PMC publication ID4926166
P698PubMed publication ID26150206

P50authorGünther DeuschlQ30501407
Torge RempeQ59678951
Thorsten BartschQ61042082
Olav JansenQ88007239
P2093author name stringChristian Wüthrich
Wolfgang Brück
Igor J Koralnik
Frank Leypoldt
Arne Wrede
Ortwin Adams
Axel Rohr
P2860cites workPlacebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosisQ28275399
The human polyomavirus, JCV, uses serotonin receptors to infect cellsQ28294207
Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarateQ28388243
Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.Q30583907
PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease SectionQ30613846
The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathyQ30689194
Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA).Q30787775
Seizures and their outcome in progressive multifocal leukoencephalopathyQ31030491
Dimethylfumarate is an inhibitor of cytokine-induced nuclear translocation of NF-kappa B1, but not RelA in normal human dermal fibroblast cellsQ31902271
Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppressionQ33510514
Progressive multifocal leucoencephalopathy in an immunocompetent patient with favourable outcome. A case reportQ33581135
Drug-induced lymphopenia: focus on CD4+ and CD8+ cellsQ33717048
Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapyQ34041795
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosisQ34300614
Progressive multifocal leukoencephalopathy: why gray and white matterQ34307762
Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathyQ34324861
A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy.Q34328813
Persistence and pathogenesis of the neurotropic polyomavirus JCQ34459843
Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarateQ34734724
Asymptomatic reactivation of JC virus in patients treated with natalizumabQ34801034
Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.Q34803324
Determinants of survival in progressive multifocal leukoencephalopathyQ35012056
JC virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individualsQ35194420
Progressive multifocal leukoencephalopathy associated with isolated CD8+ T-lymphocyte deficiency mimicking tumefactive MSQ35476415
Dimethyl fumarate associated lymphopenia in clinical practice.Q35588830
Hyperintense cortical signal on magnetic resonance imaging reflects focal leukocortical encephalitis and seizure risk in progressive multifocal leukoencephalopathyQ35590449
Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS.Q35609239
Frequent infection of cortical neurons by JC virus in patients with progressive multifocal leukoencephalopathyQ35634870
Frequency and phenotype of JC virus-specific CD8+ T lymphocytes in the peripheral blood of patients with progressive multifocal leukoencephalopathyQ35785136
Idiopathic CD4 lymphocytopenia: clinical and immunologic characteristics and follow-up of 40 patientsQ36193502
Metabolic profile of PML lesions in patients with and without IRIS: an observational studyQ36198630
Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?Q36544721
Idiopathic CD4 Lymphocytopenia: Spectrum of opportunistic infections, malignancies, and autoimmune diseasesQ37073035
A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomesQ37135539
Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patientsQ37206687
Detection of JC virus-specific cytotoxic T lymphocytes in healthy individuals.Q37492573
A case of natalizumab-associated progressive multifocal leukoencephalopathy with repeated negative CSF JCV testing.Q38068499
Identification and characterization of mefloquine efficacy against JC virus in vitroQ39877627
Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndromeQ41906877
Finger pointing to JC virus: a tale of two indexesQ42560354
Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosisQ42972411
Progressive multifocal leukoencephalopathy during fumarate monotherapy of psoriasisQ43187497
Dimethylfumarate is a potent inducer of apoptosis in human T cellsQ44693135
Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathyQ45386676
JC virus DNA load in patients with and without progressive multifocal leukoencephalopathyQ45751488
Cerebellar manifestation of PML under fumarate and after efalizumab treatment of psoriasis.Q51846870
Diagnosis of central nervous system complications in HIV-infected patientsQ58292184
Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapiesQ60962707
Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasisQ74501564
Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathyQ77336908
Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia veraQ80732978
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathyQ84114256
The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy riskQ85635552
PML in a patient treated with fumaric acidQ86649822
PML in a patient treated with dimethyl fumarate from a compounding pharmacyQ86649825
PML in a patient without severe lymphocytopenia receiving dimethyl fumarateQ87077624
PML in a patient with lymphocytopenia treated with dimethyl fumarateQ87077628
P433issue4
P407language of work or nameEnglishQ1860
P921main subjectpatientQ181600
P304page(s)501-514
P577publication date2015-10-01
P1433published inAnnals of NeurologyQ564414
P1476titleProgressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate
P478volume78